

## Authors:

Romain Briest (Sydney Children's Hospital)  
P. Ian Andrews (Department of Neurology, Sydney Children's Hospital, Randwick)  
Kartik Bhatia (University of Sydney)  
Christina Miteff (John Hunter Hospital)  
Andrew Cheung (Sydney Neurointervention Specialists)  
Jayne Antony (Children's Hospital at Westmead)  
Simone Ardern-Holmes (Children's Hospital at Westmead)  
Anne Bye (Sydney Children's Hospital)  
Michael Cardamone (Sydney Children's Hospital)  
Denise Chan (Sydney Children's Hospital)  
Russell Dale (Institute of Neuroscience and Muscle research)  
Michelle Farrar (Sydney Children's Hospital)  
Deepak Gill (Children's Hospital at Westmead)  
Sachin Gupta (Children's Hospital at Westmead)  
Alexandra Johnson (Sydney Children's Hospital)  
Tejaswi Kandula (Sydney Children's Hospital)  
John Lawson (Sydney Children's Hospital)  
Nathan Manning (Sydney Neurointervention Specialists)  
Karlee McCann (Sydney Children's Hospital)  
Alexander McQuinn (Sydney Neurointervention Specialists)  
Manoj Menezes (Children's Hospital at Westmead)  
Ferdinand Miteff (John Hunter Hospital)  
Sekhar Pillai (Sydney Children's Hospital)  
Hugo Sampaio (Sydney Children's Hospital)  
Robert Smith (John Hunter Children's Hospital)  
Gopinath Subramanian (John Hunter Children's Hospital)  
Hooi Ling Teoh (Sydney Children's Hospital)  
Christopher Troedson (TY Nelson Department of Neurology and Neurosurgery)  
Richard Webster (TY Nelson Department of Neurology and Neurosurgery)  
Jason Wenderoth (Sydney Neurointervention Specialists)  
Justin Whitley (Sydney Neurointervention Specialists)

## Eligibility for thrombolysis and outcome in pediatric acute ischemic stroke

Romain C. Briest FRACP<sup>1,\*</sup>, Kartik D Bhatia FRANZCR<sup>2</sup>, Christina Miteff FRACP<sup>3</sup>, Andrew Cheung FRANZCR<sup>4</sup>, Jayne Antony FRACP<sup>5</sup>, Simone Ardern-Holmes FRACP<sup>5</sup>, Annie Bye FRACP<sup>1</sup>, Michael Cardamone FRACP<sup>1</sup>, Denise Chan FRACP<sup>1</sup>, Russell Dale FRACP<sup>5</sup>, Michelle Farrar FRACP<sup>1</sup>, Deepak Gill FRACP<sup>5</sup>, Sachin Gupta FRACP<sup>5</sup>, Alexandra Johnson FRACP<sup>1</sup>, Tejaswi Kandula FRACP<sup>1</sup>, John Lawson FRACP<sup>1</sup>, Nathan Manning FRANZCR<sup>4</sup>, Karlee McCann RN<sup>1,5</sup>, Alexander McQuinn FRANZCR<sup>4</sup>, Manoj P Menezes FRACP<sup>5</sup>, Ferdinand Miteff FRACP<sup>3</sup>, Sekhar Pillai FRACP<sup>1</sup>, Hugo Sampaio FRACP<sup>1</sup>, Robert L Smith FRACP<sup>3</sup>, Gopinath M Subramanian<sup>3</sup>, Hooi Ling Teoh FRACP<sup>1</sup>, Christopher Troedson FRACP<sup>5</sup>, Richard Webster FRACP<sup>5</sup>, Jason Wenderoth FRANZCR<sup>4</sup>, Justin Whitley FRANZCR<sup>4</sup> P. Ian Andrews FRACP<sup>1</sup>

<sup>1</sup> Department of Neurology, Sydney Children's Hospital, Randwick, NSW, Australia

<sup>2</sup> Department of Medical Imaging, Children's Hospital at Westmead, Westmead, NSW, Australia

<sup>3</sup> Department of Neurology, John Hunter Children's Hospital, Newcastle, NSW, Australia

<sup>4</sup> Department of Neurointervention, Prince of Wales Hospital, Randwick, NSW, Australia

<sup>5</sup> T.Y. Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Westmead, NSW, Australia

**Short title:** Eligibility for thrombolysis in pediatric AIS

**Corresponding author:** Dr Romain Briest

Neurology

Level 4, Sydney Children's Hospital

High St

Randwick

Australia, 2031

**Email:** [romain.briest@health.nsw.gov.au](mailto:romain.briest@health.nsw.gov.au)

**ORCID ID:** 0009-0003-1726-2402

**Disclosures:** No funding support was applied to this work.

**Word Count:** 6000

## **ABSTRACT**

### **Background**

Thrombolysis is infrequently delivered to children with acute ischemic stroke (AIS).

Consideration of eligibility criteria and outcomes after AIS may enhance utility of thrombolysis in pediatric AIS.

### **Methods**

This retrospective observational study assessed eligibility for acute tissue plasminogen activator (tPA) and outcome in a 10-year population cohort of 151 children with AIS and a first symptomatic AIS cohort of 68 children. Outcomes among children with small vessel AIS, residual brain tumors and intracranial dissection, who are currently excluded from tPA, were explored to assess potential for benefit from tPA in these subgroups.

### **Results**

Approximately 80% of each cohort were excluded from tPA, irrespective of delay to diagnosis, related to multiple underlying disorders. All deaths occurred among patients excluded from tPA. The minority eligible for tPA had large vessel occlusions, focal cerebral arteriopathy or extracranial dissections. More than half of eligible patients had non-disabled outcomes without tPA. Approximately 40% of both cohorts had small vessel AIS, more than half of whom were excluded from tPA for additional reasons. Among those not additionally excluded, 78-88% of each cohort had non-disabled outcomes without tPA. Among 12 patients excluded from tPA due to residual brain tumors, all had additional exclusions. In contrast, patients with AIS due to intracranial dissection infrequently had additional cause for exclusion and outcomes were relatively poor.

### **Conclusions**

Only 20% of childhood AISs were eligible for tPA, irrespective of delay to diagnosis, and more than half of these patients manifest non-disabled outcomes without tPA, suggesting

relatively restricted potential for benefit with tPA. Relaxation of some exclusions for selected patients may enhance beneficial delivery of tPA.

WITHDRAWN  
see manuscript DOI for details

## Abbreviations

AIS	arterial ischemic stroke
CHW	Children's Hospital at Westmead
CTA	computed tomography angiography
ECMO	extracorporeal membrane oxygenation
ED	Emergency Department
FCA	focal cerebral arteriopathy
INR	international normalized ratio
LSV	mineralizing lenticulostriate vasculopathy
LVO	large vessel occlusion
MRI	magnetic resonance imaging
MRA	magnetic resonance angiography
MT	mechanical thrombectomy
NSW	New South Wales
PedmRS	pediatric modified Rankin Scale
PedNIHSS	pediatric National Institutes of Health Stroke Scale
SBE	subacute bacterial endocarditis
SCH	Sydney Children's Hospital
tPA	tissue plasminogen activator

## INTRODUCTION

Hyperacute reperfusion therapies with mechanical thrombectomy (MT) and medical thrombolysis improve outcome in adults with acute ischemic stroke (AIS).<sup>1</sup> Application of these acute therapies for children with AIS, however, is often limited.<sup>2-6</sup>

There are no randomized trials of any therapy in pediatric AIS. Observational studies suggest improved outcome in children treated with MT for large vessel occlusion (LVO) of the anterior and posterior circulations.<sup>7-9</sup> Efficacy of thrombolysis for pediatric AIS is even less well documented. Early attempts to offer thrombolysis were often compromised by delay and complications.<sup>10</sup> Subsequently, despite considerable effort, sufficient patients could not be recruited for a randomized trial of intravenous tissue plasminogen activator (tPA).<sup>6</sup> Australian guidelines for diagnosis and management of acute childhood stroke<sup>2</sup> and similar protocols in Canada,<sup>3</sup> Europe,<sup>4</sup> United Kingdom (UK)<sup>5</sup> and the USA,<sup>6</sup> together with safety data in children treated with tPA within 4.5 hours of symptom onset<sup>11</sup> now support thrombolysis for selected childhood AIS cases.

We were interested in the potential utility of tPA in pediatric stroke. We reviewed two cohorts of children with AIS - a 10-year population survey of pediatric AIS in the state of New South Wales (NSW), Australia,<sup>7</sup> representing the wide spectrum of childhood stroke; and 68 consecutive children presenting with a first, symptomatic AIS, representing the patients for whom rapid decisions regarding acute therapy with tPA are most relevant. We explored the proportion of patients eligible for tPA under existing protocols;<sup>2-6</sup> reasons for exclusion from tPA beyond delay to diagnosis; long-term outcomes related to eligibility for tPA; and potential utility of tPA for children with small vessel AIS, intracranial arterial dissection and residual brain tumors, who are currently excluded.

## METHODS

This retrospective, observational study of eligibility for tPA and outcomes among children

with AIS was approved by the Sydney Children's Hospital Network Human Research Ethics Committee, including waivers for consent.

## Patients

The NSW population cohort was identified from a previously-reported, multicenter, retrospective survey of pediatric, radiologically-confirmed AIS<sup>2</sup> in NSW (population approximately 8 million) from 1<sup>st</sup> January 2010 to 31<sup>st</sup> December 2019.<sup>7</sup> All three pediatric hospitals in NSW and an adult stroke center providing thrombectomy to older adolescents identified patients with AIS aged 29 days to 18 years. Patients aged 16 and 17 years were likely under-represented, as some were managed at adult hospitals. Details of data acquisition for this cohort have been reported previously.<sup>7</sup> Patients with intracranial hemorrhage, cerebral venous sinus thrombosis, meningitis-related stroke, herniation syndromes resulting in stroke, and global hypoxic-ischemic injury were excluded. All imaging was reviewed by KB. Diagnostic uncertainties were resolved by discussion with involved clinicians, KB and PIA. Clinical data was sometimes limited, but age at stroke, relationship to surgery, neuroimaging and outcome prior to January 2022 were collected.

The SCH cohort included all patients aged 29 days to 18 years presenting with acute neurologic dysfunction due to a first, symptomatic AIS to Sydney Children's Hospital (SCH) from 1<sup>st</sup> January 2010 to 31<sup>st</sup> December 2023. A subset of these patients is included in the NSW population cohort. Patients presenting before 2018 were identified retrospectively from inpatient records utilizing ICD-10 codes 163.0-163.9 plus from Neurology Outpatient records (using key words "stroke", "infarct" and "infarction"). One patient was managed at a suburban hospital after the SCH Neurointerventionalist drove to that hospital to successfully perform MT. Patients presenting after January 2018 were collected prospectively. AIS was defined by concordant clinical scenario and neuroimaging.<sup>2</sup> Neuroimaging was reviewed by PIA, unblinded to diagnoses. Studies of concern were reviewed by AC, blinded to diagnoses.

Unlike the NSW population cohort, which included all AIS, irrespective of mode of

presentation, the SCH cohort only included patients with first, symptomatic presentations of AIS. For example, patients identified by 'routine' neuroimaging after extracorporeal membrane oxygenation (ECMO), surgical or endovascular procedures, and patients with prior AIS were excluded from the SCH cohort. The aim was to identify a cohort most relevant to the time-limited decision-making process underlying delivery of thrombolysis to children with AIS. Data regarding clinical presentation, imaging, diagnoses, and outcome after AIS were collected. We defined onset of symptoms as the first symptoms attributable to AIS; triage as first report to the Emergency Department (ED) or ward staff for inpatients; and time of diagnosis as conclusion of the neuroimaging which first confirmed AIS. Pediatric National Institutes of Health Stroke Scale (PedNIHSS) at presentation was calculated retrospectively from the medical records for those presenting before 2018 and prospectively for those presenting thereafter.

### **Eligibility for tPA**

Eligibility for tPA was based upon the 2017 Australian guidelines,<sup>2</sup> which are largely concordant with international recommendations.<sup>3-6</sup> Prior to these guidelines, tPA was not sanctioned for pediatric stroke in NSW. Inclusion criteria are age > 2 years, PedNIHSS 4-24 and radiologically-confirmed AIS. Exclusion criteria include multiple risk factors for bleeding, such as traumatic brain injury, intracranial hemorrhage, significant surgery within last 10 days, intracranial surgery within the last 3 months, warfarin therapy with elevated international normalized ratio (INR > 1.4) or underlying malignancy; AIS due to specific etiologies, such as septic embolism, intracranial arterial dissection, Moyamoya or vasculitis; and delay of more than 4.5 hours since last known well. We also excluded patients with iatrogenic stroke immediately associated with endovascular treatments of intracranial vascular malformations. Patients with mild symptoms, defined as PedNIHSS < 4, were excluded from treatment with tPA because of expected spontaneous, good outcomes.



Australian<sup>2</sup> and most international<sup>4,5,9</sup> recommendations require identification of arterial wall

pathology for treatment with tPA. We specifically reviewed patients with small vessel strokes, without arterial wall abnormalities identified by magnetic resonance angiography (MRA), computed tomography angiography (CTA) or digital subtraction angiography. Within this cohort, we applied the same exclusion criteria as above, plus we excluded AIS after minor head trauma in infants and young children with mineralizing lenticulostriate vasculopathy (LSV) on the basis of the hypothesized pathogenesis and expected good outcomes.<sup>12</sup>

Patients excluded from tPA for any reason except delay to diagnosis or 'wake-up' strokes beyond 4.5 hours since last known well are designated 'excluded irrespective of delay to diagnosis'.

## **Outcome**

Outcome data was collected for both cohorts at last clinical review, at least six months after stroke. The pediatric modified Rankin Scale (PedmRS) was applied since documentation was sometimes insufficient to calculate PedNIHSS. In keeping with standardized nomenclature for non-disabled outcome<sup>13</sup> and the seminal data for tPA in adult strokes,<sup>14</sup> we defined 'good outcomes' as PedmRS of 0-1.

## **Statistical analysis**

Categorical variables were analyzed using Fisher's exact test and continuous variables using the two-tailed Mann-Whitney U test.

## **RESULTS**

The NSW population cohort included 151 AIS among 147 patients, all of whom had follow-up data beyond 6 months. The SCH first, symptomatic AIS cohort included 68 consecutive patients, 66 of whom had follow-up data beyond 6 months and 46 of whom were included in the NSW population cohort. Demographic details are shown in Table 1.

Inclusion criteria differed between the two cohorts. Cardiac surgery in NSW is performed at

Children's Hospital at Westmead. Consequently, the NSW population cohort shows the expected large proportions with known cardiac disease prior to AIS, age < 2 years in the context of congenital heart disease and cardiac surgery and cardioembolic etiology, which are less among the SCH cohort. AIS identified by 'routine' imaging, typically after cardiac surgery, ECMO or intracranial procedures, and patients with prior strokes are included in the NSW cohort but not the SCH cohort. Consequently, there was a greater proportion of patients with preceding disability in the NSW population cohort (45%) than the SCH cohort (19%) ( $p=0.001$ ). Final disease severity was greater among the NSW population cohort than the SCH cohort ( $p=0.042$ ), and non-disabled outcomes (PedmRS 0-1) were less common among the NSW cohort than the SCH cohort (61/147 [41%] and 38/65 [58%] respectively;  $p=0.037$ ).

Only a minority of AISs were eligible for treatment with tPA, irrespective of delay to diagnosis - 26/151 (17%) in the NSW population cohort and 15/68 (22%) in the SCH cohort (Table 2). Initial neuroimaging in these patients revealed LVO in 14/26 (54%) among the NSW cohort and 7/15 (47%) among the SCH cohort; focal cerebral arteriopathy (FCA) in 7/26 (27%) among the NSW cohort and 5/15 (33%) among the SCH cohort; and extracranial dissection in 5/26 (19%) among the NSW cohort and 3/15 (20%) among the SCH cohort. Five patients were treated with tPA. All presented with acute hemiparesis. LVOs were identified in four, who were also treated with MT. One patient had FCA. Two patients were treated with tPA beyond 4.5 hours after stroke onset, one following favorable CT perfusion imaging.

Outcomes beyond 6 months after AIS are available for all 26 eligible patients in the NSW cohort and 13/15 in the SCH cohort (Table 3). Among these patients, 15 (58%) in the NSW cohort and 8 (62%) in the SCH cohort had non-disabled outcomes, without tPA treatment. None died and the most severely affected individual had a final PedmRS of 3.

Approximately 80% of each cohort was ineligible for tPA, irrespective of delay to diagnosis.

Table 2 lists reasons for exclusion. Often multiple causes for exclusion pertained. For many, exclusion criteria were apparent at presentation, such as age < 2 years, recent surgery or endovascular procedure, malignancy, residual intracerebral neoplasm, residual intracerebral vascular malformation, recent lumbar puncture and PedNIHSS < 4. Some exclusion criteria became apparent with initial neuroimaging, such as intracranial hemorrhage, Moyamoya, intracranial dissection and small vessel strokes. Recognition of some exclusion criteria required synthesis of clinical and neuroimaging data, such as vasculitis and SBE. For some, ineligibility for tPA was not obvious and depended upon less-immediately available investigations.

Thirteen patients in the SCH cohort (19%) were excluded from tPA because of mild presenting features (PedNIHSS < 4, Tables 2 and 3). Diagnoses included Moyamoya in one, focal arteriopathies in three, LSV in three and other small vessel strokes in six. Final outcomes were PedmRS 0 for eight patients and PedmRS 1 for three. Two patients showed complete resolution of AIS symptoms, but one manifest pre-existing and residual CNS dysfunction related to craniopharyngioma and surgery, and one died remotely from the AIS due to underlying malignancy.

Recognizing tPA was not sanctioned for pediatric AIS in NSW before 2018, which reduced urgency for diagnosis after LVO was excluded, delays to diagnosis were frequent and additionally precluded treatment with tPA. Table 4 details diagnostic delays for the SCH cohort. Approximately half of both cohorts presented more than six hours after last known well.

Table 3 details final outcomes according to eligibility for tPA among 147 patients from the NSW cohort and 66 from the SCH cohort, including those treated with tPA and MT.

Patients potentially eligible for tPA in the NSW cohort showed less severe final disability than those ineligible for tPA ( $p=0.016$ ). This was more marked when the SCH patients presenting

with PedNIHSS < 4, considered too mildly affected to warrant treatment with tPA, were excluded ( $p=0.011$ ). Differences were not significant among the SCH cohort, although a similar trend was noted when patients presenting with PedNIHSS < 4 were excluded.

All 22 deaths occurred among patients ineligible for tPA (Tables 3 and 5). Fourteen (64%) deaths occurred remotely from the strokes, related to underlying disorders – cardiac disease and/or complications of cardiac surgery in seven, malignancy in two, non-AIS complications of genetic Moyamoya syndromes in two (one had AIS without typical Moyamoya), ‘primitive neuroectodermal tumor’ in one, cerebral hemorrhage after excision of brain abscess following severe brain trauma in one and unexpectedly in one. Eight deaths occurred in proximity to AIS – one with basilar artery thrombosis unresponsive to multiple MTs as the presenting feature of acute leukemia; one with hemorrhagic transformation of a pontine stroke in the context of an underlying, untreatable degenerative disorder; and six for whom stroke was part of the palliative decision-making process related to underlying leukemia, glioblastoma multiforme, multisystem vasculitis, genetic Moyamoya or complications of cardiac surgery.

Small vessel strokes, including LSV, occurred in 60 (40%) of the NSW cohort and 28 (41%) of the SCH cohort. Nine SCH patients, four of whom were also in the NSW cohort, presented with PedNIHSS < 4, deemed too mildly affected to warrant treatment with tPA. After excluding these patients, we explored additional exclusions and outcomes among the remainder (Table 5). Among the remaining NSW cohort, 18/56 (32%) were otherwise potentially eligible for tPA, 14 (78%) of whom had non-disabled outcomes (PedmRS 0-1) with supportive treatment alone. Thirty eight (68%) were additionally excluded from tPA and manifest more severe final disability ( $p = 0.004$ ). Among the remaining SCH cohort, 8/19 (42%) were otherwise potentially eligible for tPA, seven (88%) of whom had non-disabled outcomes (PedmRS 0-1) with supportive treatment alone. Eleven (58%) were additionally excluded from tPA and manifest marginally more severe final disability.

Ten patients across both cohorts had AIS due to intracranial dissection. All were previously well. Three with acute, severe trauma and intracranial hemorrhage and one with vasculitis were additionally excluded from tPA. Six had no additional exclusions, two of whom were treated with MT and intra-arterial stents and one with superficial temporal to middle cerebral artery branch bypass. Their final outcomes were PedmRS 0, 0, 1, 3, 3 and 3.

Among 12 patients excluded from tPA because of residual intracerebral tumor all but one from both cohorts were additionally excluded because of surgery within the last ten days, small vessel AIS, age < 2 years, PedNIHSS < 4 and/or intracranial hemorrhage. One patient was additionally excluded from tPA only due to surgery six weeks earlier. She showed persistent sequelae of the stroke equivalent to PedmRS 2, plus additional dysfunction related to the craniopharyngioma.

## DISCUSSION

The dominant finding in this study is the high proportion of pediatric AIS excluded from tPA, irrespective of delay to diagnosis. This observation was concordant in two patient cohorts: a 10-year population survey of pediatric AIS in NSW representing the wide spectrum of pediatric AIS, amongst whom 83% were excluded; and the SCH consecutive, first, symptomatic stroke cohort representing the subpopulation for whom time-limited decisions related to administration of tPA are most relevant, amongst whom 78% were excluded. This proportion excluded is even higher than in prior, smaller studies.<sup>15,16</sup> Additionally, the well-recognized delays to diagnosis of childhood AIS further reduced the proportion eligible for treatment with tPA.

Initial imaging in patients eligible for tPA irrespective of delay to diagnosis revealed LVO, FCA or extracranial dissection. These arterial pathologies are typically recognizable by CTA. In our experience, CTA is often more rapidly available than MRI/MRA. Its application may facilitate more timely diagnosis and delivery of tPA to currently eligible patients, facilitate timely MT for LVO and identify arterial diseases, such as Moyamoya, excluded from tPA.<sup>17</sup>

## Identification of LVO, FCA or extracranial dissection in patients diagnosed beyond 4.5 hours

may also prompt perfusion imaging and consideration of thrombolysis for those with favorable features, as for adult stroke.<sup>1,18</sup> Fortunately, approximately 60% of potentially eligible patients in both cohorts had non-disabled outcomes (pedmRS 0-1) without tPA treatment. The remainder of potentially eligible patients, 11/151 (7%) of the total NSW cohort and 5/68 (7%) of the total SCH cohort, represent the important subset of pediatric AIS for whom timely delivery of tPA is potentially most beneficial. It is also possible that eligible patients with non-disabled outcomes may have further improved if treated with tPA.

Among recent series of children presenting with sufficient suspicion of AIS to undergo rapid assessment and neuroimaging, most had stroke mimics and only 9-38% had AIS.<sup>17,19</sup> Together with our findings, this predicts only 1.5-8.4% of children with suspected AIS would potentially be eligible for tPA. Frequent delays to diagnosis will likely further reduce the minority realistically eligible for tPA. Additionally, more than half the patients potentially eligible for tPA in both our cohorts showed non-disabled outcomes without tPA treatment. These observations highlight the magnitude of rapid assessment and neuroimaging required to potentially provide substantial benefit from tPA among children with suspected AIS. They also speak to difficulties recruiting sufficient patients for a randomized controlled trial of thrombolysis in pediatric stroke.

Most exclusions related to bleeding risks and mild stroke severity (PedNIHSS < 4), which are concordant with adult guidelines.<sup>1</sup> That all 13 patients with documented presenting PedNIHSS < 4 had good stroke outcomes supports application of this criterion.

A specific pediatric exclusion, age less than two years, is based upon immaturity of the fibrinolytic system and different pharmacokinetics of tPA in children compared to adults.<sup>6</sup>

Recognizing that many criteria are relative rather than absolute reasons for exclusion, we explored potential for benefit with tPA in subsets of excluded patients. Small vessel AIS are eligible for, and benefit from, tPA in adults<sup>1,14</sup> but are excluded from tPA in the Australian<sup>2</sup>

and most pediatric protocols.<sup>4,6</sup> Small vessel strokes accounted for approximately 40% of all AIS in both cohorts (Tables 2, 3 and 5). After excluding SCH patients presenting with PedNIHSS < 4, 38 (68%) from the remaining NSW cohort and 11 (58%) from the remaining SCH cohort with small vessel AIS had additional reasons for exclusions from tPA (Table 5). Among those not additionally excluded from tPA, 14/18 (78%) of the NSW cohort and 7/8 (88%) of the SCH cohort had non-disabled (PedmRS 0-1) outcomes with supportive treatment alone. These observations suggest modest, although not nil, potential for benefit from tPA for children with small vessel AIS.

A growing literature suggests adults with AIS due to intracranial dissection were safely treated with tPA.<sup>20</sup> Given intracranial dissection accounted for 6-7% of all AIS in both cohorts and was frequently associated with poor outcome, might we consider tPA for pediatric AIS due to intracranial dissection without subarachnoid hemorrhage, pseudoaneurysms or other exclusions? In addition, distinction between inflammatory FCA and intracranial dissection amongst pediatric AIS patients is often difficult in the time-limited window for therapeutic thrombolysis. Rather than err on the side of not treating with tPA because of possible intracranial dissection, this adult data may prompt thrombolysis despite uncertainty regarding exact diagnosis.

Review of patients excluded due to residual intracranial tumors indicated that all 12 had additional reasons for exclusion from tPA, suggesting small potential for benefit from tPA if this exclusion criteria was relaxed.

This study also highlights the multiple pathogenic processes linked to pediatric stroke. These processes often require time to consider, thereby delaying diagnoses, as well as influencing eligibility for tPA or other therapies. They also influence outcome. For instance, all deaths in both cohorts were at least in part, and often predominantly, related to underlying pathogenic processes rather than the AIS. Although not specifically explored in this study, underlying



pathogenic processes beyond the sequelae of the strokes may also influence long term outcome in survivors.

The retrospective mode of data collection limits interpretation of these observations. The comprehensive acquisition of patients for the state-wide survey of pediatric stroke to develop the NSW cohort and the partly prospective recruitment of consecutive, first, symptomatic strokes in the SCH cohort, however, may partly mitigate this concern. Absence of some clinical details for the NSW cohort is also a limiting factor, but extra data, if anything, would likely add to the proportion excluded from tPA. That outcome data was limited to PedmRS assessment is less than comprehensive, but provided useful information easily ascertained by review of the medical records. The high retention rate of patients within the study allowed opportunity for less-easily recognized consequences of the strokes to be revealed. Compared to adult stroke studies, the numbers in these cohorts are small, but the rarity of childhood AIS often limits numbers in pediatric series. The small size of patient subsets herein reviewed suggests caution in generalization of some observations.

In conclusion, about 80% of childhood AIS are currently excluded from tPA, mostly related to the many underlying pathogeneses predisposing to stroke. That only about 20% are eligible for tPA, irrespective of delay to diagnosis, and that more than half of eligible patients have non-disabled outcomes without tPA suggests relatively restricted opportunity for substantial benefit from tPA in childhood stroke. This data may prompt imaging targeting specific arterial pathologies in eligible patients (LVO, FCA and extracranial dissection) with CTA in centers without immediate access to MRI/MRA to facilitate timely delivery of tPA (and MT) and perfusion imaging for those diagnosed beyond 4.5 hours after stroke onset. Relaxing some exclusion criteria might enhance benefit from tPA among children with AIS, such as selected patients with small vessel strokes and intracranial dissection. The rarity of AIS, the many underlying pathogeneses, the lack of empiric evidence showing benefit of tPA and the frequent spontaneous, good outcomes in childhood AIS make the rapid decisions required to offer tPA to patients with relative exclusions challenging. Realistic expectations regarding



the utility of thrombolysis in pediatric stroke, adult data related to patients with similar

underlying pathogeneses and accumulated pediatric experience with tPA may gradually

optimize benefit from thrombolysis for childhood AIS.

## **ACKNOWLEDGMENTS**

We thank the many families and clinicians involved in the care of these patients.

## **SOURCES OF FUNDING**

None

## **DISCLOSURES**

None

WITHDRAWN  
see manuscript DOI for details

## REFERENCES

1. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211
2. Mackay M, Andrews I, Cheung M, Dale R, Fahey M, Mandelstam S, Medley T, Miteff C, Monagle P, Pridmore C et al. Australian Childhood Stroke Advisory Committee. Guideline for the diagnosis and acute management of childhood stroke – 2017. <https://informme.org.au/guidelines/childhood-stroke-clinical-guidelines>
3. Boulanger JM, Lindsay MP, Gubitz G, Smith EE, Stotts G, Foley N, Bhogal S, Boyle K, Braun L, Goddard T, et al. Canadian Stroke Best Practice Recommendations for Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care, 6th Edition, Update 2018. *Int J Stroke*. 2018;13(9):949-984. doi:10.1177/1747493018786616
4. Mastrangelo M, Giordo L, Ricciardi G, De Michele M, Toni D, Leuzzi V. Acute ischemic stroke in childhood: a comprehensive review. *Eur J Pediatr*. 2022 Jan;181(1):45-58. doi: 10.1007/s00431-021-04212-x.
5. Ganesan V, Agrawal S, Alderson L, Ashton R, Baldwin N, Barber M, Barkey S, Bhate S, Cockerill H, Gordon A, et al. Stroke in childhood. Clinical guideline for diagnosis, management and rehabilitation – May 2017. <https://www.rcpch.ac.uk/sites/default/files/2021-02/Stroke%20guideline%2008.04.19%20updated%202021.pdf>
6. Rivkin MJ, deVeber G, Ichord RN, Kirton A, Chan AK, Hovinga CA, Gill JC, Szabo A, Hill MD, Scholz K, Amlie-Lefond C. Thrombolysis in pediatric stroke study. *Stroke*. 2015;46(3):880-885. doi: 10.1161/STROKEAHA.114.008210.
7. Bhatia KD, Briest R, Goetti R, Webster R, Troedson C, Dale RC, Muthusami P, Miteff C, Miteff F, Worthington J, et al. Incidence and Natural History of Pediatric Large Vessel Occlusion Stroke: A Population Study. *JAMA Neurol*. 2022;79(5):488-497. doi: 10.1001/jamaneurol.2022.0323.
8. Bhatia KD, Chowdhury S, Andrews I, Goetti R, Webster R, Troedson C, Dale RC, Muthusami P, Parra-Farinas C, Dlamini N, et al. Association Between Thrombectomy and Functional Outcomes in Pediatric Patients With Acute Ischemic Stroke From Large Vessel Occlusion. *JAMA Neurol*. 2023;80(9):910-918. doi: 10.1001/jamaneurol.2023.2303.
9. Macdonald-Laurs E, Wenderoth J, Cardamone M, Sampaio H, Andrews PI. Endovascular clot retrieval for acute ischaemic stroke due to basilar artery occlusion in childhood. *Dev Med Child Neurol*. 2020;62(10):1221-1223. doi: 10.1111/dmcn.14449.
10. Amlie-Lefond C, deVeber G, Chan AK, Benedict S, Bernard T, Carpenter J, Dowling MM, Fullerton H, Hovinga C, Kirton A, et al. Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study. *Lancet Neurol*. 2009;8(6):530-6. doi: 10.1016/S1474-4422(09)70106-1.
11. Amlie-Lefond C, Shaw DWW, Cooper A, Wainwright MS, Kirton A, Felling RJ, Abraham MG, Mackay MT, Dowling MM, Torres M, et al. Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children. *Stroke*. 2020;51(2):542-548. doi: 10.1161/STROKEAHA.119.027225.

12. Goraya JS, Berry S, Sagar K, Ahluwalia A. Stroke After Minor Head Trauma in Infants and Young Children With Basal Ganglia Calcification: A Lenticulostriate Vasculopathy? *J Child Neurol*. 2018;33(2):146-152. doi: 10.1177/0883073817750501.
13. Saver JL, Chaisinanunkul N, Campbell BCV, Grotta JC, Hill MD, Khatri P, Landen J, Lansberg MG, Venkatasubramanian C, Albers GW. Standardized Nomenclature for Modified Rankin Scale Global Disability Outcomes: Consensus Recommendations From Stroke Therapy Academic Industry Roundtable XI. *Stroke*. 2021;52(9):3054-3062. doi: 10.1161/STROKEAHA.121.034480.
14. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med*. 1995;333(24):1581-7. doi: 10.1056/NEJM199512143332401.
15. Hutchinson ML, Beslow LA, Shih EK, Licht DJ, Kimmel AC, Granath C, Ichord RN. Endovascular and thrombolytic treatment eligibility in childhood arterial ischemic stroke. *Eur J Paediatr Neurol*. 2021;34:99-104. doi: 10.1016/j.ejpn.2021.08.004.
16. Lehman LL, Kleindorfer DO, Khoury JC, Alwell K, Moomaw CJ, Kissela BM, Khatri P. Potential eligibility for recombinant tissue plasminogen activator therapy in children: a population-based study. *J Child Neurol*. 2011;26(9):1121-5. doi: 10.1177/0883073811408091.
17. Briest RC, Cheung AK, Kandula T, Cardamone M, Pillai SC, Sampaio H, Teoh HL, Webster RI, Wenderoth JD, Andrews PI. Urgent computed tomography angiography in paediatric stroke. *Dev Med Child Neurol*. 2023;65(1):126-135. doi: 10.1111/dmcn.15285.
18. Campbell BCV, Ma H, Ringleb PA, Parsons MW, Churilov L, Bendszus M, Levi CR, Hsu C, Kleinig TJ, Fatar M, Leys D, Molina C, Wijeratne T, Curtze S, Dewey HM, Barber PA, Butcher KS, De Silva DS, Bladin CF, Yassi N, Pfaff JAR, Sharma G, Bivard A, Desmond PM, Schwab S, Schellinger PD, Yan B, Mitchell PJ, Serena J, Toni D, Thijs V, Hacke W, Davis SM, Donnan GA. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. *Lancet*. 394(10193):139-147, 2019 07 13
19. Harrar DB, Salussolia CL, Kapur K, Danehy A, Kleinman ME, Mannix R, Rivkin MJ. A Stroke Alert Protocol Decreases the Time to Diagnosis of Brain Attack Symptoms in a Pediatric Emergency Department. *J Pediatr*. 2020;216:136-141.e6. doi: 10.1016/j.jpeds.2019.09.027.
20. Bernardo F, Nannoni S, Strambo D, Bartolini B, Michel P, Sirimarco G. Intravenous thrombolysis in acute ischemic stroke due to intracranial artery dissection: a single-center case series and a review of literature. *J Thromb Thrombolysis*. 2019;48(4):679-684. doi: 10.1007/s11239-019-01918-6.

**TABLE 1. DEMOGRAPHIC FEATURES**

	NSW COHORT	SCH COHORT
<b>Number of patients</b>	147	68
<b>Number of strokes</b>	151	68
<b>Age in years (median/range)</b>	6/0.1-17	10/0.6-17
<b>Gender</b>	Male 95 (63%)	Male 41 (60%)
<b>Peripheral presentation</b>	-	48 (71%)
<b>Known cardiac disease</b>	37 (25%)	5 (7%)
<b>New cardiac disease</b>	13 (9%)	4 (6%)
<b>Cardioembolic etiology</b>	50 (33%)	9 (13%)
<b>Large vessel occlusion</b>	39 (26%)	15 (22%)
<b>Mechanical thrombectomy</b>	13 (9%)	11 (16%)
<b>Treatment with tPA</b>	4 (3%)	2 (3%)
<b>Follow-up (Mean <math>\pm</math> SD)</b>	37 $\pm$ 29 months	41 $\pm$ 33 months
<b>Other disability</b>	61/135 (45%)	14 (21%)
<b>Final mRS 0-1 (&gt;6months)</b>	61/147 (41%)	38/66 (58%)
<b>Final mRS 2-5 (&gt;6months)</b>	66/147 (45%)	23/66 (35%)
<b>Deaths</b>	20/147 patients (14%)	5/66 patients (8%)

**Legend:** Known cardiac disease – cardiac disease diagnosed before onset of stroke; New cardiac disease – cardiac disease recognized after onset of stroke, including patent foramen ovale; Other disability – pre-existing dysfunction related to disease processes other than AIS (data available for 135 patients); Peripheral presentation – patients presented to local hospitals and were transported to SCH

**TABLE 2. ELIGIBILITY FOR tPA, IRRESPECTIVE OF DELAY TO DIAGNOSIS**

REASONS FOR EXCLUSION FROM TREATMENT WITH tPA	NSW COHORT (n=151)	SCH COHORT (n=68)
<b>Total eligible for tPA</b>	<b>26 (17%)</b>	<b>15 (22%)</b>
<b>Total ineligible for tPA</b>	<b>125 (83%)</b>	<b>53 (78%)</b>
Post-op<10 days	23 (15%)	4 (6%)
Intracranial op 10 days to 3 months	3 (2%)*	3 (4%)
Post-endovascular procedure	6 (4%)	1 (1%)
Intracranial hemorrhage	13 (9%)	2 (3%)
Lenticulostriate vasculopathy	10 (7%)	10 (15%)
Other small vessel strokes	50 (33%)	18 (26%)
Moyamoya	10 (7%)	7 (10%)
Residual brain tumor	10 (7%)	5 (7%)
Intracranial dissection	9 (6%)	5 (7%)
Residual vascular malformation	7 (5%)	1 (1%)
PedNIHSS<4	6 (4%)*	13 (19%)
Vasculitis	5 (3%)	3 (4%)
Malignancy	5 (3%)	2 (3%)
INR	4 (3%)	1 (1%)
Thrombocytopenia	4 (3%)	0
Large volume infarct	3 (2%)*	3 (4%)
Subacute bacterial endocarditis	3 (2%)	1 (1%)
Tumor embolism	1 (1%)	1 (1%)
LP	1 (1%)*	1 (1%)
1 exclusion criterion	60 (40%)	33 (49%)
> 1 exclusion criteria	65 (43%)	20 (29%)

**Legend:** INR - international normalized ratio > 1.4; large volume infarct – AIS consuming more than 1/3 MCA territory; LP – lumbar puncture performed within 24 hours of stroke diagnosis; ; PedNIHSS<4 - mild symptoms at presentation with Pediatric National Institutes of Health Stroke Scale < 4; Post-op<10 days – significant surgery within last 10 days; Intracranial op 10 days to 3 months - intracranial surgery beyond 10 days but within the last 3 months; Residual brain tumor – known residual tumor at the time of stroke (patients with completely resected tumors not included); Residual vascular malformation – known residual vascular malformation at the time of stroke (patients with resolved malformations not included); Thrombocytopenia – platelets < 100,000.

\* - Data only available for SCH patients, therefore likely underestimation

**TABLE 3. OUTCOME AND ELIGIBILITY FOR tPA IRRESPECTIVE OF DELAY TO DIAGNOSIS**

Final Ped mRS	ELIGIBLE		INELIGIBLE		REASONS FOR EXCLUSION
	NSW	SCH	NSW	SCH	
0	7 3 MT	3 3 MT	26 3 MT	19 2 MT	Age- 2; IC bleed- 2; IC dissection- 2; INR- 1; LP- 1; MM- 1; PedNIHSS<4- 8; post-endovasc- 1; post-op- 4; residual vascular malformation- 1; SBE- 2; small vessel- 23; tumor- 1; vasculitis- 1.
1	8 1 MT	5	20	11	Age- 10; IC bleed- 1; IC dissection- 1; INR- 1; malignancy- 1; MM- 1; PedNIHSS<4- 3; post-endovasc- 1; post-op- 2; residual vascular malformation- 1; small vessel- 18; thrombocytopenia- 1; tumor- 1; vasculitis- 2.
2	8 2 MT 3 tPA	4 2 MT 2 tPA	24 1 MT	6 1 MT	Age- 11; Col4A1- 1; IC bleed- 1; IC dissection- 1; MM- 3; PedNIHSS<4- 1; post-endovasc- 2; post-op- 6; residual vascular malformation- 3; small vessel- 13; tumor- 2; vasculitis- 2.
3	3 1 MT 1 tPA	1	25	10 1 MT	Age- 11; IC bleed- 3; IC dissection- 4; large vol- 3; MM- 3; post-endovasc- 1; post-op- 8; residual vascular malformation- 1; SBE- 1; small vessel- 5; tumor- 4.
4-5	0	0	6 1 MT	2 1 MT	IC bleed- 1; IC dissection- 1; INR- 1; MM- 2; post-op- 2; tumor- 1.
6	0	0	20 1 MT	5 1 MT	Age- 9; IC bleed- 5; IC dissection- 1; INR- 1; malignancy- 4; MM- 2; PedNIHSS<4- 1; post-endovasc- 1; post-op- 4; residual vascular malformation- 1; small vessel- 9; thrombocytopenia- 3; tumor- 3; tumor embolism- 1; vasculitis-1.
<b>Median Range</b>	1 0-3	1 0-3	2 0-6	1 0-6	

**Legend:** Age – age < 2 years; Col4A1 - pathogenic mutation in Col4A1 gene; IC bleed – intracranial hemorrhage; IC dissection – intracranial arterial dissection; INR - international normalized ratio > 1.4; large vol – AIS consuming more than 1/3 MCA territory; malignancy – leukemia or sarcoma; MM – Moyamoya; 'n' MT – number of patients treated with mechanical thrombectomy; 'n' tPA – number of patients treated with tPA; PedmRS - Pediatric modified Rankin Scale; PedNIHSS<4 - mild symptoms at presentation with Pediatric National Institutes of Health Stroke Scale < 4; post-endovasc - iatrogenic stroke associated with endovascular treatment of vascular malformations; post-op - significant surgery within last 10 days or intracranial surgery within the last 3 months; SBE – subacute bacterial endocarditis; small vessel – acute MRA, CTA or DSA without arterial wall abnormalities; thrombocytopenia – platelets < 100,000; tumor – residual intracranial tumor.

**TABLE 4. DELAYS TO DIAGNOSIS**

	<b>NSW COHORT (n=151)</b>	<b>SCH COHORT potentially eligible after initial exclusions (n=15)</b>	<b>SCH COHORT accounting for all exclusions (n=68)</b>
Diagnosis<4.5hrs	-	2 (13%)	8 (12%)
Wake-up stroke	-	6 (40%)	16 (24%)
Triage>4.5hrs	-	3 (20%)	21 (31%)
Last seen well>6hrs	80 (53%)	8 (53%)	34 (50%)
Triage<4.5hrs, dx>4.5hrs	-	8 (53%)	39 (57%)
Eligible after all exclusions	-	1 (7%)	1 (1%)
Treated with tPA	4 (3%)	2 (13%)	2 (3%)

**Legend:** Diagnosis<4.5hrs – diagnosed less than 4.5 hours after recognition of symptoms; Eligible after all exclusions – eligible for tPA accounting for both diagnostic criteria and delay to diagnosis; Triage>4.5hrs – patients presented to medical attention more than 4.5 hours after recognition of symptoms; Triage<4.5hrs, dx >4.5hrs - patients presented to medical attention less than 4.5 hours but were diagnosed more than 4.5 hours after recognition of symptoms; Wake-up stroke – last known well more than 4.5 hours before waking with symptoms.



**TABLE 5. OUTCOME & ELIGIBILITY FOR tPA AMONG PATIENTS WITH SMALL VESSEL STROKES (EXCLUDING SCH PATIENTS PRESENTING WITH PedNIHSS < 4)**

Final Ped mRS	ELIGIBLE		INELIGIBLE		REASON FOR EXCLUSION IRRESPECTIVE OF DELAY TO DIAGNOSIS
	NSW	SCH	NSW	SCH	
0	10	5	8	3	Age-1; IC bleed- 2; LSV- 3; post-endovasc- 1; post-op- 4; SBE- 1; residual vascular malformation- 1.
1	4	2	8	5	Age- 7; INR- 1; LSV- 7; malignancy- 1; post-op- 2; thrombocytopenia- 1.
2	3	1	9	1	Age- 7; Col4A1- 1; LSV- 3; post-op- 3; vasculitis- 1.
3	1	0	5	2	Age- 4; post-op- 3; tumor- 2.
4-5	0	0	0	0	
6	0	0	8	0	Age- 4; IC bleed- 1; INR- 1; malignancy- 2; post-op- 1; thrombocytopenia- 2.
<b>Median</b>	0	0	2	1	
<b>Range</b>	0-3	0-2	0-6	0-3	

**Legend:** Age – age < 2 years; Col4A1 - pathogenic mutation in Col4A1 gene; IC bleed – intracranial hemorrhage; INR - international normalized ratio > 1.4; malignancy – leukemia or sarcoma; LSV – lenticulostriate vasculopathy;<sup>13</sup> PedmRS - Pediatric modified Rankin Scale; PedNIHSS<4 - mild symptoms at presentation with Pediatric National Institutes of Health Stroke Scale < 4; post-endovasc - iatrogenic stroke associated with endovascular treatment of vascular malformations; post-op - significant surgery within last 10 days or intracranial surgery within the last 3 months; SBE – subacute bacterial endocarditis; thrombocytopenia – platelets < 100,000; tumor – residual intracranial tumor.



## Eligibility for thrombolysis irrespective of delay to diagnosis and final outcome beyond 6 months in pediatric acute ischemic stroke

